CN1633291A - 2－噁唑胺及其作为5－ht2b受体拮抗剂的应用 - Google Patents

2－噁唑胺及其作为5－ht2b受体拮抗剂的应用 Download PDF

Info

Publication number
CN1633291A
CN1633291A CNA038039532A CN03803953A CN1633291A CN 1633291 A CN1633291 A CN 1633291A CN A038039532 A CNA038039532 A CN A038039532A CN 03803953 A CN03803953 A CN 03803953A CN 1633291 A CN1633291 A CN 1633291A
Authority
CN
China
Prior art keywords
alkyl
unsubstituted
aryl
naphthalen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038039532A
Other languages
English (en)
Chinese (zh)
Inventor
A·W·奥克斯福德
R·A·博尔曼
R·A·科尔曼
K·L·克拉克
G·海德
J·A·阿彻
A·阿利
N·V·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagene Laboratories Ltd
Original Assignee
Pharmagene Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Laboratories Ltd filed Critical Pharmagene Laboratories Ltd
Publication of CN1633291A publication Critical patent/CN1633291A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA038039532A 2002-02-13 2003-02-11 2－噁唑胺及其作为5－ht2b受体拮抗剂的应用 Pending CN1633291A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0203412.2 2002-02-13
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists

Publications (1)

Publication Number Publication Date
CN1633291A true CN1633291A (zh) 2005-06-29

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038039532A Pending CN1633291A (zh) 2002-02-13 2003-02-11 2－噁唑胺及其作为5－ht2b受体拮抗剂的应用

Country Status (17)

Country Link
US (1) US7429607B2 (https=)
EP (1) EP1474140B1 (https=)
JP (1) JP4439266B2 (https=)
KR (1) KR20040084905A (https=)
CN (1) CN1633291A (https=)
AU (1) AU2003207297B2 (https=)
CA (1) CA2472762A1 (https=)
DE (1) DE60317632T2 (https=)
EA (1) EA200401077A1 (https=)
GB (1) GB0203412D0 (https=)
IL (1) IL163110A (https=)
MX (1) MXPA04007738A (https=)
NO (1) NO327465B1 (https=)
NZ (1) NZ534539A (https=)
PL (1) PL370221A1 (https=)
WO (1) WO2003068226A1 (https=)
ZA (1) ZA200406010B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299948B1 (it) 1998-04-02 2000-04-04 Azionaria Costruzioni Acma Spa Metodo e dispositivo per la formazione di gruppi di articoli appiattiti.
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
WO2005012263A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
JPWO2005079845A1 (ja) 2004-02-20 2007-08-02 アステラス製薬株式会社 片頭痛予防薬
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
DK1797038T3 (da) 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
US9464062B2 (en) 2012-11-28 2016-10-11 Temple University—Of the Commonwealth System of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트
CN116789549A (zh) * 2023-06-16 2023-09-22 山东科源化工有限公司 一种羟基乙酸乙烯酯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
AU679635B2 (en) 1994-03-11 1997-07-03 Eli Lilly And Company Method for treating 5HT-2B receptor related conditions
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ATE227710T1 (de) * 1996-04-03 2002-11-15 Takeda Chemical Industries Ltd Oxazole derivate,ihre herstellung und verwendung
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
JP2004500333A (ja) 1999-07-30 2004-01-08 ファーマジーン　ラボラトリーズ　リミテッド 胃腸管障害の治療における、２−アミノ−４−（４−フルオロナフタ−１−イル）−６−イソプロピルピリミジンの使用
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Also Published As

Publication number Publication date
NO20043799L (no) 2004-09-10
CA2472762A1 (en) 2003-08-21
EP1474140A1 (en) 2004-11-10
ZA200406010B (en) 2005-06-08
AU2003207297A1 (en) 2003-09-04
JP4439266B2 (ja) 2010-03-24
GB0203412D0 (en) 2002-04-03
WO2003068226A1 (en) 2003-08-21
DE60317632T2 (de) 2008-10-30
NZ534539A (en) 2006-02-24
NO327465B1 (no) 2009-07-06
PL370221A1 (en) 2005-05-16
DE60317632D1 (de) 2008-01-03
JP2005528341A (ja) 2005-09-22
EA200401077A1 (ru) 2005-06-30
IL163110A (en) 2010-12-30
MXPA04007738A (es) 2004-10-15
EP1474140B1 (en) 2007-11-21
AU2003207297A2 (en) 2003-09-04
US20040010022A1 (en) 2004-01-15
AU2003207297B2 (en) 2008-11-06
US7429607B2 (en) 2008-09-30
KR20040084905A (ko) 2004-10-06

Similar Documents

Publication Publication Date Title
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN1143852C (zh) 茚并、萘并和苯并芳庚并二氢噻唑衍生物、它们的制备和它们作为减食欲药物的用途
CN1184215C (zh) 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物
CN1246319C (zh) 氨基(硫)醚衍生物
CN1993346A (zh) 新颖噻吩化合物
CN1159292C (zh) 用作选择性多巴胺d3配体的芳基取代的环胺类化合物
CN1930138A (zh) 取代的吗啉和硫代吗啉衍生物
CN1544420A (zh) 用取代杂环脲抑制raf激酶
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1638768A (zh) 调节ppar活性的噻唑和噁唑衍生物
CN1225009A (zh) 五氟苯磺酰胺及其类似物
CN1727339A (zh) 三环化合物及其制备和用途
CN1444570A (zh) 非甾体抗炎药
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1761657A (zh) Ep4受体拮抗剂
CN1791412A (zh) 新化合物和它们的治疗用途
CN1221524C (zh) 治疗用的二苯基醚化合物
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN101061116A (zh) 磺酰胺化合物
CN1894231A (zh) 作为ep4受体拮抗剂的呋喃衍生物
CN1449380A (zh) 作为选择性5－羟色胺再摄取抑制剂的苯氧基苄胺衍生物
CN86102349A (zh) 制备n-[(4-哌啶基)烷基]取代的双环稠合的唑与噻唑胺之方法
CN1633291A (zh) 2－噁唑胺及其作为5－ht2b受体拮抗剂的应用
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1522253A (zh) 新颖的杂环衍生物及其医疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication